Outcomes with simultaneous administration of all-transretinoic acid (ATRA) plus chemotherapy-based regimens in older patients with newly diagnosed acute promyelocytic leukemia (APL).
| Cooperative Group, Reference . | Induction Regimen . | n . | Non- eligiblen(%) . | Median Age (range) . | CRn(%) . | Death in CRn(%) . | DFS % . | CIR % . | OS % . |
|---|---|---|---|---|---|---|---|---|---|
| Abbreviations: CR, complete remission; DFS, disease-free survival; CIR, cumulative incidence of relapse; OS, overall survival; NA, not available | |||||||||
| GIMEMA Mandelli et al (2003) | ATRA + Idarubicin | 134 | 23 (15) | 66 (60–75) | 116 (87) | 14 (12) | 59 (6y) | NA | 56 (6y) |
| European APL Ades et al (1999) | ATRA + Daunorubicin + Cytarabine | 129 | NA | 66 (62–70) | 111 (86) | 24 (19) | NA | 16 (4y) | 58 (4y) |
| PETHEMA Sanz et al (2004) | ATRA + Idarubicin | 104 | 21 (17) | NA (60–81) | 87 (84) | 8 (9) | 79 (6y) | 8.5 (6y) | NA |
| Cooperative Group, Reference . | Induction Regimen . | n . | Non- eligiblen(%) . | Median Age (range) . | CRn(%) . | Death in CRn(%) . | DFS % . | CIR % . | OS % . |
|---|---|---|---|---|---|---|---|---|---|
| Abbreviations: CR, complete remission; DFS, disease-free survival; CIR, cumulative incidence of relapse; OS, overall survival; NA, not available | |||||||||
| GIMEMA Mandelli et al (2003) | ATRA + Idarubicin | 134 | 23 (15) | 66 (60–75) | 116 (87) | 14 (12) | 59 (6y) | NA | 56 (6y) |
| European APL Ades et al (1999) | ATRA + Daunorubicin + Cytarabine | 129 | NA | 66 (62–70) | 111 (86) | 24 (19) | NA | 16 (4y) | 58 (4y) |
| PETHEMA Sanz et al (2004) | ATRA + Idarubicin | 104 | 21 (17) | NA (60–81) | 87 (84) | 8 (9) | 79 (6y) | 8.5 (6y) | NA |